Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 98

Sort by

Sort Order Select

Journal Articles

Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation

Shunsuke Nishino, Hisashi Yamamoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Shinsuke Takagi, Kazuya Ishiwata, Go Yamamoto, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 3508.

https://doi.org/10.1182/blood-2024-205008

Published: 2024

Journal Articles

What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes

Jotaro Yamamoto, Hisashi Yamamoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Shinsuke Takagi, Kazuya Ishiwata, Go Yamamoto, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 3485.

https://doi.org/10.1182/blood-2024-201930

Published: 2024

Journal Articles

Retrospective Analysis of Single-Unit Umbilical Cord Blood Transplantation in Elderly Patients (Aged 65 Years and Older) with Predominantly High-Risk Myeloid Malignancies: A Single-Institution Study

Yuki Taya, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Hisashi Yamamoto, Go Yamamoto, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 7437.

https://doi.org/10.1182/blood-2024-208778

Published: 2024

Journal Articles

Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL

Ryo Koizumi, Shinsuke Takagi, Aya Nishida, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Kazuya Ishiwata, Hisashi Yamamoto, Yuki Asano-Mori, Go Yamamoto, Atsushi Wake, Shuichi Taniguchi, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 2189.

https://doi.org/10.1182/blood-2024-203327

Published: 2024

Journal Articles

Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms

Otoya Watanabe, Hisashi Yamamoto, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 4933.

https://doi.org/10.1182/blood-2024-210383

Published: 2024

Journal Articles

Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status

Tatsuro Hirao, Hisashi Yamamoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 4920.

https://doi.org/10.1182/blood-2024-198879

Published: 2024

Journal Articles

Comparison of Myeloablative Conditioning with Cyclophosphamide and Total-Body Irradiation (Cy/TBI) Vs. Fludarabine, Melphalan, and Total-Body Irradiation (Flu/Mel/TBI) in Patients Undergoing Allogeneic Stem Cell Transplant for AML/ALL

Tomoyo Kubo, Hisashi Yamamoto, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Atsushi Wake, Naoyuki Uchida

Blood (2023) 142 (Supplement 1): 4917.

https://doi.org/10.1182/blood-2023-182732

Published: 2023

Journal Articles

Efficacy of Lisocabtagene Maraleucel for Relapsed or Refractory Aggressive B Cell Lymphoma in Our Hospital

Daisuke Kaji, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Aya Nishida, Shinsuke Takagi, Hisashi Yamamoto, Kazuya Ishiwata, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida, Go Yamamoto

Blood (2023) 142 (Supplement 1): 6931.

https://doi.org/10.1182/blood-2023-184637

Published: 2023

Journal Articles

Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation for Relapse or Refractory Peripheral T-Cell Lymphoma at Toranomon Hospital and Toranomon Hospital Kajigaya

Futoshi Yoshino, Daisuke Kaji, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Hisashi Yamamoto, Atsushi Wake, Naoyuki Uchida, Go Yamamoto

Blood (2023) 142 (Supplement 1): 6191.

https://doi.org/10.1182/blood-2023-185447

Published: 2023

Journal Articles

Excellent Outcome Following Maintenance Therapy with Gilteritinib after Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia Even in Non-Remission Status

Aya Nishida, Otoya Watanabe, Daisuke Kaji, Yuki Taya, Shinsuke Takagi, Hisashi Yamamoto, Go Yamamoto, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida

Blood (2023) 142 (Supplement 1): 4989.

https://doi.org/10.1182/blood-2023-182632

Published: 2023

Journal Articles

Single CBT As 2nd Allo-SCT Is Promising for Selected Patients with Relapsed Hematopoietic Malignancies

Otoya Watanabe, Hisashi Yamamoto, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Atsushi Wake, Naoyuki Uchida

Blood (2023) 142 (Supplement 1): 7096.

https://doi.org/10.1182/blood-2023-188946

Published: 2023

Journal Articles

Comparing Single Cord Blood Transplantation and Matched Related Donor Transplantation in Non-Remission Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 1790.

https://doi.org/10.1182/blood-2021-147645

Published: 2021

Journal Articles

Favorable Outcomes of Newly Diagnosed Intravascular Large B-Cell Lymphoma Patients Treated with R-CHOP Combined with High-Dose Methotrexate Plus Intrathecal Chemotherapy: Results from a Multicenter Phase 2 Trial (PRIMEUR-IVL)

Blood (2019) 134 (Supplement_1): 350.

https://doi.org/10.1182/blood-2019-126798

Published: 2019

Journal Articles

Low Lymphocyte Count at Day 30 after Single Cord Blood Transplantation Had Negative Impact on Survival, Because of Higher NRM Rate

Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Daisuke Kaji, MD, Yuki Taya, MD PhD, Shinsuke Takagi, Hisashi Yamamoto, MD PhD, Go Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Atsushi Wake, MD PhD, Akiko Yoneyama, MD PhD, Shigeyoshi Makino, MD PhD, Naoyuki Uchida, MD PhD, Shuichi Taniguchi, MD PhD

Blood (2019) 134 (Supplement_1): 4482.

https://doi.org/10.1182/blood-2019-130662

Published: 2019

Journal Articles

Direct Comparison of Long-Term Outcome of Allogeneic Transplantation for Myelofibrosis in Chronic and Leukemic Stage in a Single Institute

Shinsuke Takagi, Takashi Mitsuki, MD, Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Daisuke Kaji, MD, Yuki Taya, MD PhD, Aya Nishida, MD, Kazuya Ishiwata, MD, Hisashi Yamamoto, MD PhD, Go Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Naoyuki Uchida, MD PhD, Atsushi Wake, MD PhD, Shuichi Taniguchi, MD PhD

Blood (2019) 134 (Supplement_1): 5382.

https://doi.org/10.1182/blood-2019-129859

Published: 2019

Journal Articles

Clinicopathological Analysis of "Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders" Reveals a Favorable Outcome Independent of the Effectiveness of Methotrexate Discontinuation in Autoimmune Disease Patients

Daisuke Kaji, MD, Manabu Kusakabe, MD PhD, Mamiko Sakata-Yanagimoto, MD PhD, Yasuhito Suehara, MD, Keiichiro Hattori, MD PhD, Yasunori Ota, MD PhD, Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Yuki Taya, MD PhD, Shinsuke Takagi, Hisashi Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Naoyuki Uchida, MD PhD, Atsushi Wake, MD PhD, Shuichi Taniguchi, MD PhD, Go Yamamoto, MD PhD, Shigeru Chiba, MD PhD

Blood (2019) 134 (Supplement_1): 4128.

https://doi.org/10.1182/blood-2019-127521

Published: 2019

Journal Articles

Graft-Versus-Host Disease-Free, Relapse-Free Survival in Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma Provides a Novel Donor Selection Paradigm

Hiroyuki Muranushi, MD, Takero Shindo, MD PhD, Masakatsu Hishizawa, MD PhD, Masahito Tokunaga, MD PhD, Atsushi Wake, MD PhD, Nobuaki Nakano, MD, Tetsuya Eto, MD PhD, Michihiro Hidaka, MD PhD, Ilseung Choi, MD PhD, Toshihiro Miyamoto, MD PhD, Naoyuki Uchida, MD PhD, Yukiyoshi Moriuchi, MD, Yasuhiko Miyazaki, MD PhD, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Atsuta, MD PhD, Koji Kato, MD PhD

Blood (2019) 134 (Supplement_1): 2008.

https://doi.org/10.1182/blood-2019-123318

Published: 2019

Journal Articles

Pre-Engraftment Immune Reactions Has Unique Graft-Versus-Leukemia Effects after Single Cord Blood Transplantation

Yamamoto Hisashi, MD PhD, Naoyuki Uchida, MD PhD, Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Daisuke Kaji, MD, Takashi Mitsuki, MD, Yuki Taya, MD PhD, Aya Nishida, MD, Kazuya Ishiwata, MD, Shinsuke Takagi, Yuki Asano-Mori, MD PhD, Go Yamamoto, MD PhD, Atsushi Wake, MD PhD, Shuichi Taniguchi, MD PhD

Blood (2019) 134 (Supplement_1): 2041.

https://doi.org/10.1182/blood-2019-130550

Published: 2019

Journal Articles

Minimal Residual Disease (MRD) Status after Induction Therapy Is a Strong Prognostic Factor in the Treatment of Adult Ph (-) Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Study (ALL MRD2008 Study)

Koji Nagafuji, MD PhD, Toshihiro Miyamoto, MD PhD, Tetsuya Eto, MD PhD, Ryosuke Ogawa, MD PhD, Naoyuki Uchida, MD PhD, Ken Takase, MD, Noriaki Kawano, MD PhD, Tomoaki Fujisaki, MD PhD, Tomohiko Kamimura, MD PhD, Atsushi Wake, MD PhD, Hirokazu Okumura, MD PhD, Yasuhiko Miyazaki, MD PhD, Yasushi Takamatsu, MD PhD, Toshiro Kurokawa, MD PhD, Yuju Ohno, MD PhD, Shouhei Yokota, MP.Path, Koichi Akashi, MD PhD

Blood (2018) 132 (Supplement 1): 3970.

https://doi.org/10.1182/blood-2018-99-112848

Published: 2018

Journal Articles

Allogeneic Stem Cell Transplantation Overcomes Negative Impact on Relapse Rate and Progression Free Survival in 294 Non-Remission AML Patients with Adverse Cytogenetic Abnormalities Other Than Monosomal or Complex Karyotype

Mitsuhiro Yuasa, MD, Michiho Ebihara, MD, Daisuke Kaji, MD, Kosei Kageyama, MD, Aya Nishida, MD, Shinsuke Takagi, Hisashi Yamamoto, MD, Go Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Atsushi Wake, MD PhD, Akiko Yoneyama, MD PhD, Shigeyoshi Makino, MD PhD, Naoyuki Uchida, MD PhD, Shuichi Taniguchi, MD PhD

Blood (2018) 132 (Supplement 1): 3469.

https://doi.org/10.1182/blood-2018-99-116212

Published: 2018

NARROW

Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation

What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes

Retrospective Analysis of Single-Unit Umbilical Cord Blood Transplantation in Elderly Patients (Aged 65 Years and Older) with Predominantly High-Risk Myeloid Malignancies: A Single-Institution Study

Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL

Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms

Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status

Comparison of Myeloablative Conditioning with Cyclophosphamide and Total-Body Irradiation (Cy/TBI) Vs. Fludarabine, Melphalan, and Total-Body Irradiation (Flu/Mel/TBI) in Patients Undergoing Allogeneic Stem Cell Transplant for AML/ALL

Efficacy of Lisocabtagene Maraleucel for Relapsed or Refractory Aggressive B Cell Lymphoma in Our Hospital

Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation for Relapse or Refractory Peripheral T-Cell Lymphoma at Toranomon Hospital and Toranomon Hospital Kajigaya

Excellent Outcome Following Maintenance Therapy with Gilteritinib after Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia Even in Non-Remission Status

Single CBT As 2nd Allo-SCT Is Promising for Selected Patients with Relapsed Hematopoietic Malignancies

Comparing Single Cord Blood Transplantation and Matched Related Donor Transplantation in Non-Remission Acute Myeloid Leukemia

Favorable Outcomes of Newly Diagnosed Intravascular Large B-Cell Lymphoma Patients Treated with R-CHOP Combined with High-Dose Methotrexate Plus Intrathecal Chemotherapy: Results from a Multicenter Phase 2 Trial (PRIMEUR-IVL)

Low Lymphocyte Count at Day 30 after Single Cord Blood Transplantation Had Negative Impact on Survival, Because of Higher NRM Rate

Direct Comparison of Long-Term Outcome of Allogeneic Transplantation for Myelofibrosis in Chronic and Leukemic Stage in a Single Institute

Clinicopathological Analysis of "Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders" Reveals a Favorable Outcome Independent of the Effectiveness of Methotrexate Discontinuation in Autoimmune Disease Patients

Graft-Versus-Host Disease-Free, Relapse-Free Survival in Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma Provides a Novel Donor Selection Paradigm

Pre-Engraftment Immune Reactions Has Unique Graft-Versus-Leukemia Effects after Single Cord Blood Transplantation

Minimal Residual Disease (MRD) Status after Induction Therapy Is a Strong Prognostic Factor in the Treatment of Adult Ph (-) Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Study (ALL MRD2008 Study)

Allogeneic Stem Cell Transplantation Overcomes Negative Impact on Relapse Rate and Progression Free Survival in 294 Non-Remission AML Patients with Adverse Cytogenetic Abnormalities Other Than Monosomal or Complex Karyotype

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only